Overview

• Researchers reported results in AACR’s Cancer Research Communications from 832 samples drawn from cohorts in Manchester and Colorado.
• Overall accuracy reached 93% in the Colorado cohort and 92% in the Manchester cohort, with early-stage detection at 91% and 88%, respectively.
• The AOA Dx assay measures tumour-derived lipid and protein fragments in blood and uses a machine-learning model trained on thousands of patient samples.
• Company executives say the platform detects early disease more accurately than current tools, while clinicians stress the need for independent, prospective validation.
• With about 7,500 UK cases annually and often vague early symptoms, an effective blood test could support earlier diagnosis and better outcomes.